Chengdu Kanghua Biological Products Co., Ltd.

SZSE:300841 Stock Report

Market Cap: CN¥6.9b

Chengdu Kanghua Biological Products Past Earnings Performance

Past criteria checks 2/6

Chengdu Kanghua Biological Products has been growing earnings at an average annual rate of 18.2%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 12% per year. Chengdu Kanghua Biological Products's return on equity is 15.4%, and it has net margins of 34.4%.

Key information

18.2%

Earnings growth rate

14.0%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate12.0%
Return on equity15.4%
Net Margin34.4%
Next Earnings Update17 Aug 2024

Recent past performance updates

Recent updates

We Think Chengdu Kanghua Biological Products (SZSE:300841) Can Stay On Top Of Its Debt

Jun 26
We Think Chengdu Kanghua Biological Products (SZSE:300841) Can Stay On Top Of Its Debt

Chengdu Kanghua Biological Products Co., Ltd.'s (SZSE:300841) Prospects Need A Boost To Lift Shares

Feb 27
Chengdu Kanghua Biological Products Co., Ltd.'s (SZSE:300841) Prospects Need A Boost To Lift Shares

Revenue & Expenses Breakdown

How Chengdu Kanghua Biological Products makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:300841 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 241,611553605230
31 Dec 231,577509611253
30 Sep 231,382484553238
30 Jun 231,421531558218
31 Mar 231,458568562208
01 Jan 231,447598545180
30 Sep 221,567729555161
30 Jun 221,400893515113
31 Mar 221,32286450783
01 Jan 221,29282950779
30 Sep 2199364839767
30 Jun 211,13647845772
31 Mar 211,11944446872
31 Dec 201,03940844558
30 Sep 201,08544245551
30 Jun 2073928532437
31 Mar 2058121626622
31 Dec 1955518727523
30 Sep 1942510124321
31 Dec 1855915431219
31 Dec 17262741324
31 Dec 16937536
31 Dec 157112275

Quality Earnings: 300841 has high quality earnings.

Growing Profit Margin: 300841's current net profit margins (34.4%) are lower than last year (39%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300841's earnings have grown by 18.2% per year over the past 5 years.

Accelerating Growth: 300841's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 300841 had negative earnings growth (-2.6%) over the past year, making it difficult to compare to the Biotechs industry average (-3.2%).


Return on Equity

High ROE: 300841's Return on Equity (15.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.